Visceral adiposity as a predictor of survival in patients with epithelial ovarian cancer receiving platinum and taxane-based chemotherapy.

被引：2
|
作者：
Staley, Stuart-Allison Moffat
Tucker, Katherine
Oldan, Jorge
Moore, Dominic T.
Newton, Meredith
Ertel, Michelle
West, Lindsay
Bae-Jump, Victoria
机构：
[1] Univ N Carolina, Sch Med, Chapel Hill, NC 27515 USA
[2] Univ N Carolina, Div Gynecol Oncol, Chapel Hill, NC 27515 USA
[3] Duke Univ, Med Ctr, Durham, NC USA
[4] Univ N Carolina, Lineberger Comprehens Canc Ctr, Biostat & Data Management, Chapel Hill, NC 27515 USA
[5] Univ N Carolina, Dept Obstet & Gynecol, Chapel Hill, NC 27515 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.e17031
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17031
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Sarcopenia as a predictor of survival in patients with epithelial ovarian cancer (EOC) receiving platinum and taxane-based chemotherapy.
    Staley, Stuart-Allison Moffat
    Tucker, Katherine
    Newton, Meredith
    Ertel, Michelle
    Zhang, Yingao
    Doherty, Irene
    Gehrig, Paola A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] Visceral adiposity as a predictor of chemotherapy toxicity in patients with ovarian cancer receiving platinum and taxane-based chemotherapy
    Tucker, K.
    Staley, A.
    Oldan, J. D.
    Newton, M.
    Ertel, M.
    West, L.
    Moore, D. T.
    Bae-Jump, V. L.
    GYNECOLOGIC ONCOLOGY, 2019, 154 : 112 - 113
  • [3] Sarcopenia as a predictor of chemotherapy toxicity in patients with ovarian cancer receiving platinum and taxane-based chemotherapy.
    Tucker, Katherine
    Staley, Stuart-Allison Moffat
    Newton, Meredith
    Ertel, Michelle
    Zhang, Yingao
    Doherty, Irene
    Gehrig, Paola A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] Sarcopenia as a predictor of survival and chemotoxicity in patients with epithelial ovarian cancer receiving platinum and taxane-based chemotherapy
    Staley, S. Allison
    Tucker, Katherine
    Newton, Meredith
    Ertel, Michelle
    Oldan, Jorge
    Doherty, Irene
    West, Lindsay
    Zhang, Yingao
    Gehrig, Paola A.
    GYNECOLOGIC ONCOLOGY, 2020, 156 (03) : 695 - 700
  • [5] Impact of epoetin beta on the survival of anemic patients with ovarian cancer receiving platinum-based chemotherapy.
    Reed, N
    Chan, S
    Hayward, C
    Burger, HU
    Huinink, WT
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 479S - 479S
  • [6] ESTROGEN RECEPTOR BETA AS A PREDICTIVE MARKER IN OVARIAN CANCER PATIENTS TREATED WITH PLATINUM AND TAXANE-BASED CHEMOTHERAPY
    Bogush, T.
    Basharina, A.
    Dudko, E.
    Vikhlanceva, N.
    Vorobjeva, I.
    Bogush, E.
    Tjulandina, A.
    Davydov, M.
    Tjulandin, S.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1803 - 1803
  • [7] Durability of clinical benefit in metastatic epithelial ovarian cancer patients treated with pegilodecakin monotherapy or in combination with platinum plus taxane-based chemotherapy
    Autio, K. A.
    Naing, A.
    Hung, A.
    Oft, M.
    Leveque, J.
    Falchook, G. S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [8] Muscle and Joint Symptoms in Breast Cancer Patients Receiving Taxane-Based Chemotherapy
    van Draanen, J.
    Stacey, E.
    Dent, R.
    Gallo-Hershberg, D.
    Pasetka, M.
    Giotis, A.
    Kan, K.
    van Draanen, L.
    Fang, T.
    Lee, V.
    Walker, S.
    DeAngelis, C.
    CANCER RESEARCH, 2010, 70
  • [9] Bowel resection at the time of primary debulking for epithelial ovarian carcinoma: Outcomes in patients treated with platinum and taxane-based chemotherapy
    Estes, Jacob M.
    Leath, Charles A., III
    Straughn, J. Michael, Jr.
    Rocconi, Rodney P.
    Kirby, Tyler O.
    Huh, Warner K.
    Barnes, Mack N., III
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2006, 203 (04) : 527 - 532
  • [10] Predicting toxicity of platinum and taxane-based chemotherapy in older patients with gynecologic cancer
    Yoshida, Hiroyuki
    Shintani, Daisuke
    Kawashima, Naoyuki
    Fujiwara, Keiichi
    JOURNAL OF BUON, 2020, 25 (02): : 736 - 742
12345